Skip to main
NAGE

ChromaDex Corp (NAGE) Stock Forecast & Price Target

ChromaDex Corp (NAGE) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Niagen Bioscience is poised for long-term success due to its leadership in NAD+ science, innovative NAD+-boosting solutions and strategic initiatives such as the introduction of a pen-like autoinjector, establishing a USP monograph for nicotinamide riboside chloride, expanding its 503B network, and partnering with cruise ships. The company has multiple methods to drive growth, and with the increasing focus on health and wellness, it is likely to continue to outperform its competitors in the longevity and injectable industries, which are projected to grow at impressive rates.

Bears say

Niagen Bioscience is currently facing a lawsuit against regulators over the FDA's decision to allow the sale of NMN products, potentially providing a long-term tailwind. Additionally, their launch of a clinician-directed telehealth platform for their Niagen Plus product and the availability of their Niagen At-Home Injection Kit may expand their addressable market and drive revenue in the coming quarters. Despite a recent pullback in the stock price, the risk/reward remains attractive with Niagen trading at lower earnings and EBITDA multiples compared to other supplement companies, and the potential value of their Ataxia Telangiectasia opportunity could add $5 in share value.

ChromaDex Corp (NAGE) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ChromaDex Corp (NAGE) Forecast

Analysts have given ChromaDex Corp (NAGE) a Strong Buy based on their latest research and market trends.

According to 3 analysts, ChromaDex Corp (NAGE) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ChromaDex Corp (NAGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.